These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3464099)

  • 1. Interferon alfa-2b in the treatment of chronic granulocytic leukemia.
    Bergsagel DE; Haas RH; Messner HA
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):29-34. PubMed ID: 3464099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alfa-2b in the treatment of chronic granulocytic leukemia.
    Bergsagel DE; Haas RH; Messner HA
    Invest New Drugs; 1987; 5 Suppl():S9-17. PubMed ID: 3298136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
    Bergsagel DE; Messner H
    Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alfa-2b in the treatment of chronic myelogenous leukemia.
    Niederle N; Kloke O; Osieka R; Wandl U; Opalka B; Schmidt CG
    Semin Oncol; 1987 Jun; 14(2 Suppl 2):29-35. PubMed ID: 3473689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alfa-2b in the management of chronic granulocytic leukemia.
    Bergsagel DE
    Cancer Treat Rev; 1988 Jan; 15 Suppl A():15-20. PubMed ID: 3422593
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b.
    Niederle N; Kloke O; May D; Becher R; Osieka R; Schmidt CG
    Invest New Drugs; 1987; 5 Suppl():S19-25. PubMed ID: 3474219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Ph'-positive chronic myelogenous leukemia (CML) with recombinant interferon alfa-2b (Intron A).
    Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inveradi D; Bernasconi P; Mancini M; Grignani F; Bernasconi C
    Cancer Treat Rev; 1988 Jan; 15 Suppl A():21-6. PubMed ID: 3277708
    [No Abstract]   [Full Text] [Related]  

  • 8. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.
    Talpaz M; Kantarjian HM; McCredie K; Trujillo JM; Keating MJ; Gutterman JU
    N Engl J Med; 1986 Apr; 314(17):1065-9. PubMed ID: 3457264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II study of continuous-infusion high-dose human lymphoblastoid interferon and the in vitro sensitivity of leukemic progenitors in nonlymphocytic leukemia.
    Mirro J; Dow LW; Kalwinsky DK; Dahl GV; Weck P; Whisnant J; Murphy SB
    Cancer Treat Rep; 1986 Mar; 70(3):363-7. PubMed ID: 3456833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferons in the treatment of multiple myeloma.
    Cooper MR; Welander CE
    Cancer; 1987 Feb; 59(3 Suppl):594-600. PubMed ID: 3802025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of metastatic malignant melanoma with recombinant interferon alfa-2b.
    Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Falcoff E; Schwab D; Lerminier M; Pouillart P
    Invest New Drugs; 1987; 5 Suppl():S61-3. PubMed ID: 3597003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. A preliminary report.
    Pangalis GA; Griva E
    Cancer; 1988 Mar; 61(5):869-72. PubMed ID: 3338053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [alpha 2-interferon: preliminary treatment results in chronic myeloid leukemia].
    Niederle N; Kloke O; Doberauer C; Becher R; Beelen DW; Schmidt CG
    Dtsch Med Wochenschr; 1986 May; 111(20):767-72. PubMed ID: 3516621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferons in the treatment of multiple myeloma.
    Cooper MR
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):13-20. PubMed ID: 3764441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy.
    Vonderheid EC; Thompson R; Smiles KA; Lattanand A
    Arch Dermatol; 1987 Jun; 123(6):757-63. PubMed ID: 3579357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Busulfan versus busulfan-interferon as maintenance therapy in chronic myeloid leukemia].
    López Hernández MA; Flores-Chapa JD; Trueba Christy E; Borbolla Escoboza JR; Carrillo Rosales T
    Rev Invest Clin; 1996; 48(4):281-7. PubMed ID: 8966391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INTRON A (interferon alfa-2b): clinical overview.
    Spiegel RJ
    Cancer Treat Rev; 1985 Dec; 12 Suppl B():5-16. PubMed ID: 3914355
    [No Abstract]   [Full Text] [Related]  

  • 18. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of multiple myeloma with recombinant interferon alfa-2a.
    Ohno R; Kimura K
    Cancer; 1986 Apr; 57(8 Suppl):1685-8. PubMed ID: 3948139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.